Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM, which is expected to positively impact its financial performance in 2025 and beyond [1] Group 1: Agreements - The technology transfer and supply agreement involves the transfer of insulin glargine technology and the supply of active pharmaceutical ingredients and injection solutions [1] - The total amount of the supply framework agreement is expected to be no less than RMB 3 billion, with the final amount determined by actual order values [1] - The signing of the contracts has been approved within the company's general manager's authority and has followed internal approval procedures [1] Group 2: Financial Impact - The execution of these contracts is anticipated to have a positive effect on the company's operating performance in 2025 and subsequent years [1] - The agreements are expected to enhance the overall profitability of the company [1]